Compare Enveric Biosciences Inc (ENVB) vs Wix.Com Ltd (WIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs Wix.Com Ltd — how do they compare? Enveric Biosciences Inc trades at $1.51 (market cap $6.69M), while Wix.Com Ltd trades at $74.13 (market cap $3.05B). The key difference: Wix.Com Ltd is far larger — about 455.9× Enveric Biosciences Inc's market cap, and Wix.Com Ltd is trading nearer its 52-week high, Enveric Biosciences Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Enveric Biosciences Inc for 14 Days and Wix.Com Ltd for 62 Days on average.
| ENVB | WIX | |
|---|---|---|
Market Cap | $6.69M | $3.05B |
Volume | 41,141 | 748,691 |
Sector | Health | Technology |
52-Week High | $10.80 | $145.54 |
52-Week Low | $1.27 | $40.43 |
Typical Hold Time | 14 Days | 62 Days |
Enterprise Value | -$1.60M | $4.13B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.495, up 1.7% on the day, but technical indicators signal a bearish trend with moving averages and ADX pointing lower. The company reported no revenue in 2025 and a net loss of $8.77 million, though it has consistently beaten EPS expectations. Recent news includes a new U.S. patent allowance for its non-hallucinogenic mescaline derivatives and participation in an investment conference.
The outlook remains speculative given the lack of revenue and negative profitability, but analyst consensus is bullish with 75% buy ratings. Key risks include the pre-revenue biotech model and dependence on successful drug development. Upside potential hinges on clinical progress and regulatory milestones for its psychiatric therapeutics pipeline.
Wix stock trades at $72.97, down 1.27% today, amid a bearish technical signal and mixed earnings. Recent quarters show volatility with a Q1 2026 miss but a Q2 beat. Revenue growth is solid, reaching $1.99B in 2025, but profitability remains weak with a negative net income margin. The stock faces headwinds from a securities class action lawsuit, with multiple law firms announcing deadlines in late September 2026.
The outlook is cautious; analyst consensus is bullish with a $77 price target, but high valuation ratios and legal risks offset growth potential. Investors should weigh strong revenue trends against profitability challenges and near-term sentiment pressure from litigation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About Wix.Com Ltd
Wix.com Ltd is a cloud-based development platform provider for millions of registered users worldwide. The company is engaged in web development and management that provides an easy-to-use powerful cloud-based platform of products through a freemium model. Its core products consist of three web editors: the Wix Editor, intended for users with basic technological skills, Wix ADI, intended for novice users and Corvid, intended for more tech-savvy users. The company's web development technology is built based on HTML5 and offers HTML5 compatible capabilities, web design and layout tools, domain hosting, and other marketing and workflow management applications and services. The geographic segments include North America, Europe, Latin America, Asia and others.
Read more on WIX →
